Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands
Stefano Cavalieri(University of Milan), Laura D. Locati(University of Pavia), Salvatore Lo Vullo(Azienda Sanitaria Locale di Asti), Carlo Resteghini(Humanitas University), Cristiana Bergamini(Fondazione IRCCS Istituto Nazionale dei Tumori), Laure Van Breda(KU Leuven), Esther Hauben(Universitair Ziekenhuis Leuven), Lisa Licitra(University of Milan), Vincent Vander Poorten(KU Leuven), Salvatore Alfieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppina Calareso(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesca Platini(Fondazione IRCCS Istituto Nazionale dei Tumori), Ester Orlandi(Fondazione IRCCS Istituto Nazionale dei Tumori), M.C. Cau(Azienda Ospedaliera G. Brotzu), Paul M. Clément(Universitair Ziekenhuis Leuven), Luigi Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Bossi(Humanitas University)
Cited by 40
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
|Cancer|2020|1.3k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994